Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Chinese Patent Office
Federal Trade Commission
Queensland Health
Boehringer Ingelheim

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Therapeutic compounds
Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Inventor(s): Helleday; Thomas (Stockholm, SE), Curtin; Nicola (Tyne and Wear, GB)
Assignee: Cancer Research Technology Limited (London, GB) Pfizer, Inc. (New York, NY)
Filing Date:Jul 23, 2004
Application Number:10/898,653
Claims:1. A method for treating cancer in a mammal, wherein the cancer is caused by a genetic defect in a gene that mediates homologous recombination, wherein the gene is at least one of BRCA1 and BRCA2, the method comprising: selecting the mammal having the genetic defect; and administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula III: ##STR00005## or a pharmaceutically acceptable salt thereof, wherein the compound is used as a direct cytotoxic agent.

2. The method according to claim 1, wherein the compound is the compound of the formula I.

3. The method according to claim 2, wherein the compound of the formula I is in the form of a phosphate salt.

4. The method of claim 1, wherein the cancer is breast cancer.

5. The method of claim 1, wherein the genetic defect is the absence of BRCA1 and/or BRCA2.

6. The method of claim 1, wherein the genetic defect is in the expression of BRCA1 and/or BRCA2.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: